Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00264368
Status:
TERMINATED
Last Update Posted:
2007-06-28
First Post:
2005-12-09
Brief Title:
Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy
Sponsor:
University of Oslo School of Pharmacy
Organization:
University of Oslo School of Pharmacy
Study Overview
Official Title:
Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy
Status:
TERMINATED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In order to optimize anti-cytomegalovirus CMV treatment with ganciclovir GCV in patients with multi organ failure treated with continuous renal replacement therapy RRT more information about ganciclovir pharmacokinetics in this setting is needed
The primary objective is to describe the pharmacokinetics of ganciclovir in critically ill patients with acute renal failure treated with continuous renal replacement therapy with a special emphasis on the extra-renal clearance and distribution volume
Secondary objectives are to investigate if any co-factors such as serum creatinine weight general hydration status rest function of the native kidneys etc can help to describe the pharmacokinetics of GCV in these patients on continuous RRT as well as the relative influence of filtrations and dialysis on GCV elimination during different modalities of the treatment
The primary objective is to describe the pharmacokinetics of ganciclovir in critically ill patients with acute renal failure treated with continuous renal replacement therapy with a special emphasis on the extra-renal clearance and distribution volume
Secondary objectives are to investigate if any co-factors such as serum creatinine weight general hydration status rest function of the native kidneys etc can help to describe the pharmacokinetics of GCV in these patients on continuous RRT as well as the relative influence of filtrations and dialysis on GCV elimination during different modalities of the treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None